Giuseppe Giaccone

Research interests

Publications

• Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917346

• Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.74.6065

• The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

  Journal of Thoracic Oncology · 2017 · 10.1016/j.jtho.2017.04.011

• The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

  Journal of Thoracic Oncology · 2016 · https://doi.org/10.1016/j.jtho.2015.09.009

• The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

  Journal of Thoracic Oncology · 2016 · https://doi.org/10.1016/j.jtho.2016.03.025

• Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.62.1342

• Classification of current anticancer immunotherapies

  Oncotarget · 2014 · 10.18632/oncotarget.2998

• Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

  JAMA · 2014 · https://doi.org/10.1001/jama.2014.3741

• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

  Journal of Thoracic Oncology · 2013 · https://doi.org/10.1097/jto.0b013e318290868f

• Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(13)70310-3

• Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

  Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-11-3090

• American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.31.8923

• Targeting the dynamic HSP90 complex in cancer

  Nature reviews. Cancer · 2010 · 10.1038/nrc2887

• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

  The Lancet Oncology · 2010 · 10.1016/s1470-2045(10)70112-1

• American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.5622

• Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer

  JNCI Journal of the National Cancer Institute · 2007 · 10.1093/jnci/djk093

• Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

  Journal of Clinical Oncology · 2005 · 10.1200/jco.20005.14.589

• Cell Death Independent of Caspases: A Review

  Clinical Cancer Research · 2005 · 10.1158/1078-0432.ccr-04-2223

• Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.02.7078

• Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.07.215

• Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.08.001

• Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.10.038

• A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

  PubMed · 2002

• Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.

  Journal of Clinical Oncology · 1998 · 10.1200/jco.1998.16.1.145

• Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

  Journal of Clinical Oncology · 1997 · 10.1200/jco.1997.15.5.2090

Current projects

No projects listed.